Racial disparities in treatment initiation between Black and White older adults with multiple myeloma: A SEER-Medicare analysis.

Matthew Roger LeBlanc,Xi Zhou,Christopher Edward Jensen,Jennifer Leigh Lund,Christopher D. Baggett,Bradford E. Jackson,Stephanie B. Wheeler,Sam Rubinstein,Rachel Hirschey,Sascha Alexander Tuchman,Thomas William LeBlanc,Katherine Elizabeth Reeder-Hayes

DOI: https://doi.org/10.1200/op.2023.19.11_suppl.145

2023-11-01

JCO Oncology Practice

Abstract:145 Background: We have previously identified racial disparities in multiple myeloma (MM) treatment initiation within 12 months of diagnosis. Black MM patients (60.6%) were significantly less likely to initiate treatment than White MM patients (69.5%). This current study aimed to explore the extent to which Black/White (B/W) disparities in MM treatment initiation were explained by differences in the distribution of demographic and health characteristics. Methods: We identified Black and White adults (66+) diagnosed with MM 2007 to 2017 in linked SEER-Medicare data. Patients were required to have 12 months of continuous Medicare Parts A and B pre- and post-diagnosis and Medicare Part D for 12 months post-diagnosis or until death. Our outcome was MM treatment initiation within 12 months of diagnosis and our independent variable was race (Black or White) as identified in SEER. Covariates thought to confound the relationship between race and MM treatment initiation were added to successive binomial regression models to estimate risk differences and 95% confidence limits (CL). Model 1 included only race. Model 2 added age and sex. Model 3 added Medicare low-income subsidy status and census tract poverty. Model 4 added rurality and SEER region. Model 5 added comorbidity and predicted frailty. Results: Our cohort (n=10,666) consisted of 1,649 Black and 9,017 White older adults with MM. Distributions of all individual, area-level and health characteristics differed significantly by race. In bivariate analysis all characteristics, except for sex and rurality, were significantly associated with treatment initiation. B/W risk differences remained significant across models and ranged from 3.7% (CL=0.9, 6.5) to 10.7% (CL=8.2, 13.2). Covariates explained some, but not all, of the B/W disparities in MM treatment initiation (Table 1). Conclusions: After accounting for differences in demographic and health characteristics, Black MM patients remained significantly less likely to initiate treatment within 12 months. Our study identified several factors that if addressed could attenuate B/W treatment initiation disparities. Further investigation is needed to understand how these factors contribute to treatment disparities, in order to develop health equity interventions to address them. Our results also suggest that there are additional unidentified factors contributing to disparity in MM treatment initiation. These factors must be identified and explored as we work to eliminate B/W disparities in MM treatment.[Table: see text]

oncology